In future drug development, therapies that target and modify LR-MSC function, such as monoclonal antibody-guided vector for siRNA [49], may be the strategy for treating pulmonary fibrosis by knockdown CHOP of LR-MSC. Here, DDIT3 is linked to pulmonary fibrosis.